BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 19544140)

  • 21.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
    Terasawa T; Nagai H
    Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
    Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
    Leuk Lymphoma; 2007 Aug; 48(8):1522-30. PubMed ID: 17701583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.
    Awan UE; Siddiqui N; SaadUllah M; Bashir H; Farooqui ZS; Muzaffar N; Mahmmood MT
    J Pak Med Assoc; 2013 Jun; 63(6):725-30. PubMed ID: 23901673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma.
    Zhang X; Fan W; Hu YY; Li ZM; Xia ZJ; Lin XP; Zhang YR; Liang PY; Li YH
    Chin J Cancer; 2015 Jun; 34(6):264-71. PubMed ID: 26063296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
    Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
    J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD10 expression in diffuse large B-cell lymphomas does not influence survival.
    Fabiani B; Delmer A; Lepage E; Guettier C; Petrella T; Brière J; Penny AM; Copin MC; Diebold J; Reyes F; Gaulard P; Molina TJ;
    Virchows Arch; 2004 Dec; 445(6):545-51. PubMed ID: 15517363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
    Coiffier B; Reyes F;
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):7-15. PubMed ID: 15934513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.
    Quak E; Hovhannisyan N; Lasnon C; Fruchart C; Vilque JP; Musafiri D; Aide N
    Haematologica; 2014 Jun; 99(6):e84-5. PubMed ID: 24584350
    [No Abstract]   [Full Text] [Related]  

  • 36. The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.
    Ziakas PD; Poulou LS; Voulgarelis M; Thanos L
    Leuk Lymphoma; 2012 Nov; 53(11):2166-74. PubMed ID: 22512238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
    Kobe C; Dietlein M; Fuchs M
    Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
    [No Abstract]   [Full Text] [Related]  

  • 38. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.
    Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
    Leuk Lymphoma; 2007 Aug; 48(8):1539-47. PubMed ID: 17701585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
    Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
    J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.